Latest news with #OncoInnovations
Associated Press
21-07-2025
- Business
- Associated Press
Onco-Innovations Appoints Dr. Dennis Hall to Scientific & Clinical Advisory Board
VANCOUVER, BC / ACCESS Newswire / July 21, 2025 / Onco-Innovations Limited(CBOE CA:ONCO)(Frankfurt:W1H)(WKN:A3EKSZ) ('Onco' or the 'Company') is pleased to announce the appointment of Dr. Dennis Hall, Professor of Chemistry at the University of Alberta, to its Scientific and Clinical Advisory Board. Dr. Hall is internationally recognized for his pioneering work in organoboron chemistry, catalysis, and medicinal chemistry, including the development of DNA repair inhibitors. He currently holds the Tier 1 Canada Research Chair in Boron Chemistry for Catalysis and Drug Discovery, and leads a multidisciplinary research team dedicated to the development of novel synthetic and biological applications of boron-containing compounds.[1] With over 175 peer-reviewed publications, two books, and 15 book chapters, Dr. Hall's contributions span catalysis, heterocyclic chemistry, and medicinal chemistry. He has mentored more than 75 graduate students and postdoctoral fellows, and his work has been widely cited with over 18,000 citations and an h-index of 70.[2] Among his numerous accolades are the Arthur C. Cope Scholar Award (2024) from the American Chemical Society[3], the R. U. Lemieux Award (2021) from the Canadian Society for Chemistry[4], and a Killam Research Fellowship (2019-2021). He was elected a Fellow of the Royal Society of Canada in 2017. [5] As part of his role, Dr. Hall will serve on the Scientific and Clinical Advisory Board and provide strategic advice to the Company on its Research and Development agenda, including clinical discovery, synthesis and manufacturing, pre-clinical testing, and clinical translation plans associated with Polynucleotide Kinase 3 Phosphatase (PNKP) Inhibitor Technology NP/A83. He will also collaborate with the Company's scientific and clinical leadership, as well as external partners, to advance oncology-focused innovations. 'Dr. Hall's appointment marks a significant step in bridging advanced synthetic chemistry with translational oncology. His expertise in boron-based drug discovery is uniquely aligned with our mission to develop precision therapies, and we look forward to leveraging his insight as we push our PNKP Inhibitor Technology toward the clinic,' stated Thomas O'Shaughnessy, CEO of Onco-Innovations. About Onco-Innovations Limited Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours. ON BEHALF OF ONCO-INNOVATIONS LIMITED, 'Thomas O'Shaughnessy' Chief Executive Officer For more information, please contact: Thomas O'Shaughnessy Chief Executive Officer Tel: + 1 888 261 8055 [email protected] Forward-Looking Statements Caution. This news release contains forward-looking statements relating to the further development, potential commercialization and benefits of the Company's technologies, the prospects of the Company, and the Company's business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as 'will', 'may', 'potential', 'should', 'anticipate', 'expects' and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to further develop, prove out or commercialize its technologies, and other risks detailed from time to time in the filings made by the Company with securities regulators. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law. [1] [2] [3] [4] [5] SOURCE: Onco-Innovations Limited press release
Associated Press
12-07-2025
- Business
- Associated Press
Onco-Innovations Signs Agreement with Redwood AI to Advance Discovery and Evaluation of Its PNKP Inhibitor Technology
VANCOUVER, BC / ACCESS Newswire / July 11, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H,WKN: A3EKSZ) ('Onco' or the 'Company') is pleased to announce that it has entered into a services agreement with Redwood AI Inc. (Redwood AI). This collaboration marks continued advancement of Onco's mission to accelerate the development of its exclusively-licensed Polynucleotide Kinase Phosphatase (PNKP) Compound (the 'Technology') and to extend its proprietary knowledge through discovery. This proprietary compound aims to target a range of solid tumours by enhancing sensitivity to radiation and DNA-damaging chemotherapies, offering the potential to exploit specific genetic susceptibilities in cancer. Through this agreement with Redwood AI, Onco gains access to Redwood AI's AI-driven chemistry tools that have the potential to unlock critical efficiencies in drug development, thereby carrying the potential to reduce synthesis complexity, refine compound design, and expand the pipeline of viable analogs. This effort is aimed at reinforcing Onco's technical capabilities at a crucial preclinical phase, with the goal of improving scalability, safety, and discovery precision. Under the scope of the agreement, Redwood AI will provide multi-pronged support across synthesis evaluation, cheminformatics, and organ-specific toxicity prediction for the Technology and its structural analogs. This includes independent reviews of third-party chemistry proposals and the use of Redwood's proprietary in-silico modelling tools. In simpler terms, these efforts are intended to deepen Onco's understanding of its Technology by supporting structure-based refinement and mechanistic insight. These efforts are part of Onco's broader strategy to efficiently progress toward First-in-Human studies. Redwood AI is a Vancouver-based artificial intelligence company harnessing artificial intelligence to accelerate drug synthesis and development. Founded by a team with deep roots in chemistry, AI, and drug manufacturing, including origins from Stanford1, Redwood AI is focused on overcoming one of the pharmaceutical industry's most persistent challenges - drug synthesis. By automating a substantial portion of the traditionally manual steps involved in synthesis, Redwood's technology aims to support more accurate, scalable, and cost-effective drug creation, with the goal of helping research teams move from discovery to development faster and with greater efficiency. 'The pace of innovation in cancer therapeutics depends on how quickly we can turn complex data into actionable decisions. Redwood AI's platform has the potential to enable us to explore synthesis strategies, evaluate risks, and optimize compound design with greater speed and precision. This kind of insight not only strengthens our scientific direction but also has the potential to accelerate our timeline towards clinical trials,' stated Thomas O'Shaughnessy, CEO of Onco-Innovations. About Onco-Innovations Limited Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours. ON BEHALF OF ONCO-INNOVATIONS LIMITED, 'Thomas O'Shaughnessy' Chief Executive Officer For more information, please contact: Thomas O'Shaughnessy Chief Executive Officer Tel: + 1 888 261 8055 [email protected] Forward-Looking Statements Caution. This news release contains forward-looking statements, including in relation to the prospects of the Company, and the Company's business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as 'will', 'may', 'potential', 'should', 'anticipate', 'expects' and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law. 1 SOURCE: Onco-Innovations Limited press release
Yahoo
25-06-2025
- Business
- Yahoo
Onco-Innovations' CEO to Host Special Investors' Conference Call on Wednesday, July 2, 2025
VANCOUVER, BC / / June 25, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H), (WKN:A3EKSZ) ("Onco" or the "Company") is pleased to announce that Mr. Thomas O'Shaughnessy, Onco-Innovations' CEO, will host a special investors' conference call, on Wednesday, July 2, 2025 at 2:00 p.m. PST/5:00 p.m. ET/11:00 p.m. CET. Participants are invited to send in advance questions for Mr. O'Shaughnessy to address during the conference, by submitting to investors@ Please call in 10 minutes before the conference call starts and stay on the line. CALL INTO THE LIVE EVENT: Conference Link "Dial Me": (Conference Link's 'Dial Me' feature lets participants join the call instantly-no dial-in or hold time. By entering their name, company, email, and phone number, the platform will call them directly to connect.) or Participant Toll-Free Number: 888-304-1803International / Direct Dial: 848-488-9277Germany: +49 69 5899 64215 Conference ID: ONCO The Company will issue a press release after the conclusion of the conference call. About Onco-Innovations Limited Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours. ON BEHALF OF ONCO-INNOVATIONS LIMITED, "Thomas O'Shaughnessy"Chief Executive Officer For more information, please contact: Thomas O'ShaughnessyChief Executive OfficerTel: + 1 888 261 8055investors@ Forward-Looking Statements Caution. This news release contains forward-looking statements, including in relation to the prospects of the Company, and the Company's business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "potential", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law. SOURCE: Onco-Innovations Limited View the original press release on ACCESS Newswire Sign in to access your portfolio
Yahoo
26-05-2025
- Business
- Yahoo
Onco-Innovations Announces Start of Manufacturing of Preclinical Testing Material for Its PNKP Inhibitor Technology by Dalton Pharma
VANCOUVER, BC / / May 26, 2025 / Onco-Innovations Limited (CBOE:ONCO) (Frankfurt:W1H, WKN:A3EKSZ) ("Onco" or the "Company") is pleased to announce that Dalton Pharma Services ("Dalton") has commenced activities to manufacture material for preclinical testing of the Company's exclusively-licensed nanoparticle-formulated Polynucleotide Kinase 3'-Phosphatase (PNKP) inhibitor technology. This important step marks the beginning of the transition from early-stage research and development to process scale-up and production for preclinical testing, enabling the generation of material needed for preclinical testing and planned future regulatory submissions which are key activities on the path toward clinical translation. The current phase of work includes process optimization and scale-up manufacturing aimed at producing 50 grams of Onco's proprietary PNKP inhibitor, known as A83B4C63. This material will be used in preclinical studies, including in-vitro and in-vivo testing, and is intended to support regulatory preparations for an Investigational New Drug (IND) submission in the United States, which the Company plans on making this year. Dalton, a leading Canadian contract development and manufacturing organization (CDMO), brings deep technical expertise and regulatory compliance capabilities to the project. In 2021, researchers from the University of Alberta published two peer-reviewed studies evaluating Onco-Innovations' nanoparticle-formulated PNKP inhibitor, A83B4C63, in preclinical models of colorectal cancer. The June study[1] demonstrated that treatment with the nanoparticle-encapsulated PNKP inhibitor significantly extended median survival in PTEN-deficient colorectal cancer-bearing mice to 60 days, compared to 23 days in untreated controls. The December study[2] found that combining the nanoparticle-formulated PNKP inhibitor with radiation therapy enhanced tumor growth delay in colorectal cancer models, without significant toxicity to healthy tissues. These findings support further development of the PNKP inhibitor as a targeted therapeutic approach in oncology. "This marks an important inflection point in our development roadmap, as manufacturing now begins to generate the material necessary to support future preclinical evaluation. We are now taking another tangible step toward translating a novel scientific approach towards potential therapeutic development, setting the stage for the next critical phases ahead," stated Thomas O'Shaughnessy, CEO of the Company. About Dalton Pharma ServicesDalton Pharma Services, established in 1986 and based in Toronto, Canada, is a Health Canada-approved and FDA-inspected GMP contract provider of integrated chemistry, drug development, and manufacturing services to the pharmaceutical and biotechnology industries. With over 35 years of experience, Dalton offers a comprehensive range of in-house services, including drug discovery, flow chemistry, formulation and process development, custom synthesis, cGMP sterile fill/finish, cGMP API manufacturing, and dosage form manufacturing. This integration at a single location enhances adaptability, flexibility, and cost-effectiveness, accelerating drug discovery and development programs. Dalton's commitment to quality, speed, and flexibility has been recognized with CMO Leadership Awards from Life Science Leader in 2016, 2017, and 2018 across categories such as Quality, Reliability, Capabilities, Expertise, Compatibility, and Development.[3] About Onco-Innovations LimitedOnco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours. ON BEHALF OF ONCO-INNOVATIONS LIMITED,"Thomas O'Shaughnessy"Chief Executive Officer For more information, please contact:Thomas O'ShaughnessyChief Executive OfficerTel: + 1 888 261 8055investors@ Forward-Looking Statements Caution. This news release contains forward-looking statements relating to the further development, potential commercialization and benefits of the Company's technologies, including its PKNP Inhibitor Technology, the Company's ability to complete further preclinical or other research and development activities, and the Company's plans with respect to pursuing an IND, and the prospects of the Company, and the Company's business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "potential", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to further develop, prove out or commercialize its technologies (including its PKNP Inhibitor Technology), the failure to submit an NDA or to pursue further regulatory or preclinical trials, the failure to receive regulatory approval in respect of its research and development activities, and other risks detailed from time to time in the filings made by the Company with securities regulators. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law. [1] Sadat et al. A synthetically lethal nanomedicine delivering novel inhibitors of polynucleotide kinase 3′-phosphatase (PNKP) for targeted therapy of PTEN-deficient colorectal cancer. J Control Release. 2021 Jun 10;334:335-352. doi:10.1016/ [2] Sadat et al. Nano-Delivery of a Novel Inhibitor of Polynucleotide Kinase/Phosphatase (PNKP) for Targeted Sensitization of Colorectal Cancer to Radiation-Induced DNA Damage. Front Oncol. 2021 Dec 23;11:772920. doi: 10.3389/fonc.2021.772920 [3] SOURCE: Onco-Innovations Limited View the original press release on ACCESS Newswire
National Post
22-05-2025
- Business
- National Post
Onco-Innovations Uplists to Cboe Canada
Article content TORONTO — Cboe Canada Inc. ('Cboe Canada') is pleased to announce that Onco-Innovations Limited ('Onco'), a Canadian-based company dedicated to cancer research and treatment, has uplisted to Cboe Canada and is available for trading under the ticker symbol ONCO. Article content Article content Onco has a core mission to prevent and cure cancer through cutting edge science. The company holds an exclusive global license to patented technology targeting solid tumors — and is now expanding into AI-driven analytics for multimodal real-world data. Article content 'Onco-Innovations is at a pivotal stage,' said Thomas O'Shaughnessy, CEO of Onco. 'Our growth now extends beyond drug development into AI-powered research, with a view to creating faster, smarter pathways to new cancer therapies. This convergence of science and technology positions Onco as a next-generation oncology company ready to tackle some of the biggest challenges in the field.' Article content 'Joining Cboe is more than a listing — it's a strategic alignment,' added O'Shaughnessy. 'It gives us the tools to deepen investor engagement, expand our network, and accelerate our journey toward transforming the future of cancer therapy.' Article content Cboe Canada's commitment to supporting innovative, high-growth companies and delivering global reach makes it a natural partner for Onco's ambitious vision. Article content 'It is an honour to welcome Onco to the growing roster of Cboe Listed issuers,' remarked Tanya Rowntree, Head of Listings at Cboe Canada. 'Their move to a Tier 1 listing on Cboe reflects both their strategic growth trajectory and the confidence in our platform to support next-generation innovators. Onco now benefits from enhanced access to capital, greater liquidity, and increased visibility among investors and institutions alike.' Article content Investors can trade shares of ONCO through their usual investment channels, including discount brokerages and full-service dealers. To explore all listed securities on Cboe Canada, click here. Article content Cboe Canada is home to some of the most innovative Canadian and international growth companies, ETFs from Canada's largest ETF issuers, and more than 120 Canadian Depositary Receipts (CDRs). Cboe consistently facilitates 15% of all volume traded in Canadian listed securities. Article content About Cboe Canada Article content Cboe Canada is Canada's Tier 1 stock exchange providing a best-in-class listing experience for issuers that are shaping the economies of tomorrow. Fully operational since 2015, Cboe Canada lists companies and investment products seeking a robust and internationally recognized platform that enables investor trust, quality liquidity, and broad awareness including unfettered access to market data. Article content Cboe Canada is part of Cboe Global Markets, the leading securities and derivatives exchange for the world stage. With exchanges in North America, Europe and Asia Pacific, Cboe is harnessing its global network to equip Issuers with essential capital markets solutions. Article content Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to prevent and cure cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours, setting new standards in cancer treatment. Onco is focused on advancing personalized therapies that improve cancer outcomes and set new standards in oncology research. Article content Article content Article content Article content Article content
